JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on February 20, 2003; DOI: 10.1124/jpet.102.046987

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Erratum
Right arrow An erratum has been published
Right arrow All Versions of this Article:
jpet.102.046987v1
305/2/625    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kapur, S.
Right arrow Articles by Nobrega, J. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kapur, S.
Right arrow Articles by Nobrega, J. N.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Mental Health

Vol. 305, Issue 2, 625-631, May 2003

Antipsychotic Dosing in Preclinical Models Is Often Unrepresentative of the Clinical Condition: A Suggested Solution Based on in Vivo Occupancy

Shitij Kapur , Susan C. VanderSpek, Barbara A. Brownlee and José N. Nobrega

Centre for Addiction and Mental Health, Toronto, Ontario, Canada (S.K., S.C.V., B.A.B., J.N.N.); Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada (S.K., J.N.N.)

What is the appropriate dose of an antipsychotic in an animal model? The literature reveals no standard rationale across studies. This study was designed to use in vivo dopamine D2 receptor occupancy as a cross-species principle for deriving clinically comparable doses for animal models. The relationship between dose, plasma levels, and in vivo dopamine D2 receptor occupancy was established in rats for a range of doses administered as a single dose or multiple doses (daily injections or osmotic minipump infusions) for five of the most commonly used antipsychotics. As a single dose, haloperidol (0.04-0.08 mg/kg), clozapine (5-15 mg/kg), olanzapine (1-2 mg/kg), risperidone (0.5-1 mg/kg), and quetiapine (10-25 mg/kg) reached clinically comparable occupancies. However, when these "optimal" single doses were administered as multiple doses, either by injection or by a mini-pump, it led to no or inappropriately low trough (24-h) occupancies. This discrepancy arises because the half-life of antipsychotics in rodents is 4 to 6 times faster than in humans. Only when doses 5 times higher than the optimal single dose were administered by pump were clinically comparable occupancies obtained (e.g., haloperidol, 0.25 mg/kg/day; olanzapine, 7.5 mg/kg/day). This could not be achieved for clozapine or quetiapine due to solubility and administration constraints. The study provides a rationale as well as clinically comparable dosing regimens for animal studies and raises questions about the inferences drawn from previous studies that have used doses unrepresentative of the clinical situation.

0022-3565/03/3052-0625$07.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Schizophr BullHome page
U. Meyer, E. Spoerri, B. K. Yee, M. J. Schwarz, and J. Feldon
Evaluating Early Preventive Antipsychotic and Antidepressant Drug Treatment in an Infection-Based Neurodevelopmental Mouse Model of Schizophrenia
Schizophr Bull, October 8, 2008; (2008) sbn131v1.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. R. Ahmed, V. V. Gurevich, K. N. Dalby, J. L. Benovic, and E. V. Gurevich
Haloperidol and Clozapine Differentially Affect the Expression of Arrestins, Receptor Kinases, and Extracellular Signal-Regulated Kinase Activation
J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 276 - 283.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
M. Fell, J. Neill, N. Anjum, L. Peltola, and K. Marshall
Investigation into the influence of a high fat diet on antipsychotic-induced weight gain in female rats
J Psychopharmacol, March 1, 2008; 22(2): 182 - 186.
[Abstract] [PDF]

Home page
 J. Neurosci.Home page
A.-N. Samaha, P. Seeman, J. Stewart, H. Rajabi, and S. Kapur
"Breakthrough" Dopamine Supersensitivity during Ongoing Antipsychotic Treatment Leads to Treatment Failure over Time
J. Neurosci., March 14, 2007; 27(11): 2979 - 2986.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. V. Terry Jr. and S. P. Mahadik
Time-Dependent Cognitive Deficits Associated with First and Second Generation Antipsychotics: Cholinergic Dysregulation as a Potential Mechanism
J. Pharmacol. Exp. Ther., March 1, 2007; 320(3): 961 - 968.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Natesan, K. A. Svensson, G. E. Reckless, J. N. Nobrega, K. B. L. Barlow, A. M. Johansson, and S. Kapur
The Dopamine Stabilizers (S)-(-)-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-Methanesulfonylphenyl)-1-propyl-piperidine (ACR16) Show High in Vivo D2 Receptor Occupancy, Antipsychotic-Like Efficacy, and Low Potential for Motor Side Effects in the Rat
J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 810 - 818.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. V. Terry Jr., V. Parikh, D. A. Gearhart, A. Pillai, E. Hohnadel, S. Warner, H. A. Nasrallah, and S. P. Mahadik
Time-Dependent Effects of Haloperidol and Ziprasidone on Nerve Growth Factor, Cholinergic Neurons, and Spatial Learning in Rats
J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 709 - 724.
[Abstract] [Full Text] [PDF]

Home page
 Proc R Soc BHome page
J.P Webster, P.H.L Lamberton, C.A Donnelly, and E.F Torrey
Parasites as causative agents of human affective disorders? The impact of anti-psychotic, mood-stabilizer and anti-parasite medication on Toxoplasma gondii's ability to alter host behaviour
Proc R Soc B, April 22, 2006; 273(1589): 1023 - 1030.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
F. Fumagalli, A. Frasca, M. Sparta, F. Drago, G. Racagni, and M. A. Riva
Long-Term Exposure to the Atypical Antipsychotic Olanzapine Differently Up-Regulates Extracellular Signal-Regulated Kinases 1 and 2 Phosphorylation in Subcellular Compartments of Rat Prefrontal Cortex
Mol. Pharmacol., April 1, 2006; 69(4): 1366 - 1372.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
N. Hiroi, H. Zhu, M. Lee, B. Funke, M. Arai, M. Itokawa, R. Kucherlapati, B. Morrow, T. Sawamura, and S. Agatsuma
A 200-kb region of human chromosome 22q11.2 confers antipsychotic-responsive behavioral abnormalities in mice
PNAS, December 27, 2005; 102(52): 19132 - 19137.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
T. E. Kippin, S. Kapur, and D. van der Kooy
Dopamine Specifically Inhibits Forebrain Neural Stem Cell Proliferation, Suggesting a Novel Effect of Antipsychotic Drugs
J. Neurosci., June 15, 2005; 25(24): 5815 - 5823.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
P. Seeman, D. Weinshenker, R. Quirion, L. K. Srivastava, S. K. Bhardwaj, D. K. Grandy, R. T. Premont, T. D. Sotnikova, P. Boksa, M. El-Ghundi, et al.
Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis
PNAS, March 1, 2005; 102(9): 3513 - 3518.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.